1Based on: Kho v. CA
Facts: Elena is a local entrepreneur who sells a popular skin-whitening cream called "Kutis Filipina." She secured a copyright and a patent registration for the name "Kutis Filipina" and the unique diamond-shaped container it comes in. A year later, a rival company, Derma-Plus, began selling its own skin cream in an identical diamond-shaped container with the name "Kutis Filipina." Elena immediately filed for a writ of preliminary injunction to stop Derma-Plus, arguing that as the copyright and patent holder of the name and container, she has the absolute exclusive right to them. Derma-Plus argues that a name and a container are not valid subjects of copyright or patent.
Essay Question: Will Elena's application for a writ of preliminary injunction based on her copyright and patent registrations prosper? Explain, distinguishing the appropriate Intellectual Property rights.
No, Elena's application for a writ of preliminary injunction will not prosper.
Under Philippine Intellectual Property Law, trademark, copyright, and patent are mutually exclusive rights that cannot be interchanged. A trademark distinguishes the goods of an enterprise and specifically includes stamped or marked containers. In contrast, copyright is confined to literary and artistic works, while a patent is meant for new, industrially applicable technical solutions.
In this case, the name "Kutis Filipina" and its diamond-shaped container are proper subjects of a trademark, not a copyright or a patent. Elena’s copyright and patent registrations do not guarantee her the exclusive right to use the name and container because they are not the appropriate intellectual property rights to protect those specific assets.
Therefore, since Elena failed to prove prior registration or use of the name and container as a trademark, she has no clear and unmistakable right to exclude Derma-Plus. The injunction must be denied.
2Based on: Pearl & Dean (Phil.), Inc. v. Shoemart, Inc.
Facts: Ad-Master Corp. conceptualized a specific type of illuminated advertising display unit called the "Lumi-Box." Ad-Master secured a Certificate of Copyright Registration for the engineering and technical drawings of the Lumi-Box under the classification of "pictorial illustrations." Ad-Master pitched the units to Mega-Mall Inc., but the deal fell through. A few years later, Ad-Master discovered that Mega-Mall Inc. had hired third-party fabricators to build exact replicas of the Lumi-Box based on Ad-Master's design, installing them across all its malls. Ad-Master sued Mega-Mall Inc. for copyright infringement, arguing that the copyright over the technical drawings extends to the physical manufacture of the boxes.
Essay Question: Does Ad-Master's copyright over the technical drawings give it the exclusive right to prevent Mega-Mall Inc. from manufacturing the physical Lumi-Box? Decide with legal basis.
No, Ad-Master's copyright over the technical drawings does not give it the exclusive right to prevent Mega-Mall Inc. from manufacturing the physical Lumi-Box.
Jurisprudence dictates the "Idea vs. Expression" dichotomy, wherein copyright protection extends only to the description or expression of an object, and not to the object itself. Furthermore, the Supreme Court has ruled that a utilitarian object or invention can only be protected by a patent ("No patent, no protection").
Here, the Lumi-Box is a utilitarian object. Ad-Master’s copyright only protects the technical drawings as pictorial illustrations from being unlawfully copied as drawings. To protect the exclusive right to manufacture and use the physical box itself, Ad-Master should have secured a patent.
Consequently, Ad-Master cannot use a copyright certificate to secure the exclusivity of a patentable invention and avoid the rigorous examination required for patents. Mega-Mall Inc. is not liable for copyright infringement.
3Based on: Juan v. Juan
Facts: In 2010, Mateo opened a successful chain of barbershops named "Buhok Ko." His brother, Lucas, became jealous and wanted to disrupt the business. Lucas researched and found out that "Buhok Ko" is actually the exact title of a copyrighted Filipino folk song registered in 1965 by a famous composer. Lucas filed a petition to cancel Mateo's trade name registration for "Buhok Ko," arguing before the court that nobody can appropriate a copyrighted song title as a business name because the intellectual property right already belongs to the song's composer.
Essay Question: Is Lucas correct in asserting that a copyrighted song title cannot be used as a valid trade name for a business? Explain the distinction.
No, Lucas is incorrect in his assertion.
The Supreme Court has clarified that copyright and trade names belong to completely different legal domains. A copyright is an exclusive right granted to the author or originator of literary and artistic productions (such as musical compositions). On the other hand, a trade name is a designation adopted and used by a person to denominate the goods they market, the services they render, or the business they conduct.
In this scenario, "Buhok Ko" is protected under copyright law as a musical composition. However, Mateo is using "Buhok Ko" not as a song, but as a trade name to designate and distinguish his barbershop business. The existence of a copyrighted song title does not automatically bar the appropriation of those same words as a trade name for a business.
Thus, provided there is no confusion between the musical composition and the barbershop, Mateo's use of the name is perfectly valid, and Lucas's petition to cancel the trade name should be dismissed.
4Based on: In-N-Out Burger, Inc. v. Sehwani, Inc.
Facts: "Sizzle & Shake" is a world-famous American fast-food chain that has never operated in the Philippines. However, they recently filed a trademark application with the Philippine Intellectual Property Office (IPO). During the process, they discovered that a local Philippine corporation, Local Bites Inc., opened a restaurant using the exact "Sizzle & Shake" name, copying their unique red-and-white checkered menu board, and even printing "representing Sizzle & Shake USA" on their receipts. Sizzle & Shake filed an administrative complaint for unfair competition with the IPO. Local Bites Inc. moved to dismiss, arguing two things: (1) Unfair competition cases are under the exclusive jurisdiction of regular civil courts, not the IPO; and (2) they cannot be guilty of unfair competition because Sizzle & Shake does not even do business in the Philippines.
Essay Question: Rule on the two arguments raised by Local Bites Inc. Does the IPO have jurisdiction, and are the elements of unfair competition present?
The Intellectual Property Office (IPO) has jurisdiction over the case, and Local Bites Inc. is guilty of unfair competition.
First, Section 10 of the Intellectual Property Code expressly grants the IPO's Bureau of Legal Affairs original jurisdiction in administrative complaints for violations of intellectual property rights. Regular courts do not have sole and exclusive jurisdiction over unfair competition cases; they hold concurrent jurisdiction with the IPO. Second, an action for unfair competition does not require the foreign corporation to have a registered mark or to be doing business in the Philippines, provided the essential elements are met: confusing similarity in the general appearance of the goods and an intent to deceive the public.
Applying this to the facts, Local Bites Inc. deliberately copied the exact name "Sizzle & Shake," the red-and-white color scheme, and even printed misleading statements on their receipts indicating they represented the USA brand. This creates a confusing similarity in the presentation of the goods and clearly infers an actual fraudulent intent to pass off their goods as those of the famous American chain.
Therefore, the IPO correctly has jurisdiction to hear the administrative complaint, and Local Bites Inc. is liable for unfair competition.
5Based on: Roma Drug v. RTC
Facts: Health-First Pharmacy, a local drugstore in Manila, bypassed the authorized local distributor of a life-saving, patented hypertension drug manufactured by Global Pharma. Instead, Health-First directly imported genuine boxes of the patented drug from India, where it was already introduced to the market by Global Pharma's authorized licensees. Health-First sold the imported drugs at a much lower price. The authorized local distributor requested a police raid on Health-First, claiming that the imported drugs are legally "counterfeit" under older special penal laws because they bypassed the local patent monopoly.
Essay Question: Under the Intellectual Property Code as amended by the Universally Accessible Cheaper and Quality Medicines Act (R.A. No. 9502), is Health-First Pharmacy liable for patent infringement or illegal importation? Explain the applicable limitation on patent rights.
No, Health-First Pharmacy is not liable for patent infringement or illegal importation.
Under Section 72 of the Intellectual Property Code, as amended by the Universally Accessible Cheaper and Quality Medicines Act (R.A. No. 9502), the rule of "International Exhaustion" or parallel importation is recognized. A patent owner cannot prevent third parties from importing a patented drug or medicine once it has been introduced anywhere in the world by the patent owner or by an authorized party.
In this case, the patented hypertension drug was already introduced to the market abroad by Global Pharma's authorized licensees. As a result, Global Pharma's exclusive patent rights over those specific goods were exhausted. R.A. No. 9502 expressly grants any private third party, like Health-First Pharmacy, the right to import these genuine medicines directly.
Because the later law (R.A. No. 9502) allows this parallel importation, it effectively repeals any conflicting provisions of older special laws that previously criminalized the act. Health-First's actions are completely legal.
6Based on: Phil Pharmawealth, Inc. v. Pfizer, Inc.
Facts: Med-Tech Corp holds Philippine Letters Patent No. 9988 for a specialized surgical adhesive, which explicitly expired on December 31, 2023. In March 2024, Med-Tech discovered that a competitor, Generic-Surge, started bidding to supply the exact same surgical adhesive to government hospitals. Med-Tech filed a complaint for patent infringement and sought a preliminary injunction, arguing that Generic-Surge is violating their established intellectual property rights.
Essay Question: Can the court validly issue a writ of preliminary injunction to stop Generic-Surge from manufacturing and selling the surgical adhesive? Discuss the term of patent rights.
No, the court cannot validly issue a writ of preliminary injunction to stop Generic-Surge.
The law clearly states that the exclusive right of a patentee to make, use, and sell a patented product exists only during the term of the patent. Under the Intellectual Property Code, the term of a patent is limited to twenty (20) years from the filing date of the application.
Here, Med-Tech Corp's patent for the surgical adhesive explicitly expired on December 31, 2023. Upon its expiration, the statutory monopoly ended, and the invention fell into the public domain. It is now free for the public, including competitors like Generic-Surge, to manufacture, use, and sell.
Since Med-Tech no longer possesses any exclusive property rights over the surgical adhesive, it has no clear and unmistakable right to be protected. Consequently, an injunction cannot be issued.
7Based on: Smith Kline Beckman Corp. v. CA
Facts: Chem-Pro Inc. holds a patent for a specific chemical compound, "Compound Alpha," which is highly effective at eliminating agricultural pests. The patent claims strictly define the use and synthesis of Compound Alpha. A rival company, Agri-Grow, releases a pesticide using a different chemical, "Compound Beta." Compound Beta is not mentioned anywhere in Chem-Pro's patent. Chem-Pro sues Agri-Grow for patent infringement, arguing that while Compound Beta isn't literally in the patent, it achieves the exact same result (killing pests), and therefore infringes under the "Doctrine of Equivalents." However, during trial, Chem-Pro fails to present expert testimony proving that Compound Beta operates through the same chemical means or mode of operation as Compound Alpha.
Essay Question: Is Agri-Grow liable for patent infringement under the Doctrine of Equivalents? Explain the test used by the Supreme Court.
No, Agri-Grow is not liable for patent infringement under the Doctrine of Equivalents.
The Doctrine of Equivalents provides that infringement occurs when a device appropriates a prior invention by incorporating its innovative concept and performs substantially the same function, in substantially the same way, to achieve substantially the same result (the Function-Means-Result test). In all patent infringement cases, the burden of proof rests squarely on the plaintiff.
While Chem-Pro proved that Compound Beta achieves the same result (killing pests) and performs the same function as Compound Alpha, they failed to establish the critical middle element. Chem-Pro did not present expert testimony or technical evidence to prove that Compound Beta operates by substantially the same chemical means or mode of operation as the patented Compound Alpha.
Because Chem-Pro failed to satisfy all three prongs of the Function-Means-Result test, the claim for infringement under the Doctrine of Equivalents must fail.
8Based on: E.I. Dupont De Nemours and Co. v. Director
Facts: In 1995, a foreign pharmaceutical company filed a patent application for a revolutionary diabetes medication. In 1996, the Intellectual Property Office (IPO) mailed an office action requiring a response. The company's local lawyer received it but completely forgot about it, leading the IPO to declare the application abandoned. The lawyer died shortly after. The pharmaceutical company failed to check on the status of their application until 2008—twelve years later. They filed a petition to revive the application, arguing excusable negligence due to their counsel's death. Meanwhile, several local generic manufacturers had already begun producing the drug, significantly lowering its price for the public.
Essay Question: Should the Director of the IPO grant the petition to revive the abandoned patent application? Discuss the rules on revival and the role of public interest.
No, the Director of the IPO should not grant the petition to revive the abandoned patent application.
The rules on patent procedure require strict adherence. An abandoned application may only be revived if a petition is filed within a mandatory period of four (4) months from the date of abandonment, upon a showing of excusable negligence. Furthermore, a patent is a statutory monopoly granted subject to public interest, and leniency in procedure must be weighed against this social objective.
In this scenario, the pharmaceutical company filed the petition to revive twelve years late. The rules do not allow for a 12-year extension, and the negligence of the company's counsel binds the client, especially since the company itself was negligent in failing to follow up on its application for over a decade. Crucially, the drug in question is a life-saving medication. Reviving the patent after such a long delay would unjustifiably extend a monopoly and prejudice the public interest by stifling the affordable generic competition that is already benefiting the public.
Therefore, due to the inexcusable delay and the overriding public interest in access to affordable medicines, the petition must be denied.